Global Thalassemia Clinical Trial Pipeline Highlights 2019 - Track Competition, Identifying Partners, Evaluate Opportunities - ResearchAndMarkets.com

The "Global Thalassemia Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Mercredi, juin 12, 2019
Information
Tags: 
Professional services, Consulting, Health, Articles, Clinical research, Design of experiments, Drug discovery, Clinical trial, Pharmaceutical industry, Thalassemia, Gene therapy
⚠generated by AI ↴
Résumé
Key Points: 
  • The "Global Thalassemia Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Thalassemia Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Thalassemia market.
  • It covers emerging therapies for Thalassemia in active clinical development stages including early and late stage clinical trials.
  • The report provides Thalassemia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.


The "Global
Thalassemia Clinical Trial Pipeline Highlights - 2019" report
has been added to ResearchAndMarkets.com's offering.

Thalassemia Pipeline Highlights - 2019, provides most up-to-date
information on key pipeline products in the global Thalassemia market.
It covers emerging therapies for Thalassemia in active clinical
development stages including early and late stage clinical trials. The
pipeline data presented in this report helps executives for tracking
competition, identifying partners, evaluating opportunities, formulating
business development strategies, and executing in-licensing and
out-licensing deals.

Clinical Trial Stages:

The report provides Thalassemia pipeline products by clinical trial
stages including both early and late stage development - phase 3
clinical trials, phase 2 clinical trials, phase 1 clinical trials,
preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Thalassemia pipeline products by their dominant
mechanism of action/drug class. This helps executives categorize
products based on their drug class and also assess the strengths and
weaknesses of compounds.

Company:

The report provides Thalassemia pipeline products by the company.

Short-term Launch Highlights:

Find out which Thalassemia pipeline products will be launched in the US
and Ex-US till 2024.

Summary:

  • Thalassemia phase 3 clinical trial pipeline products
  • Thalassemia phase 2 clinical trial pipeline products
  • Thalassemia phase 1 clinical trial pipeline products
  • Thalassemia preclinical research pipeline products
  • Thalassemia discovery stage pipeline products
  • Thalassemia pipeline products short-term launch highlights

Key Topics Covered:

1. Thalassemia Pipeline by Stages

2. Thalassemia Phase 3 Clinical Trial Insights

3. Thalassemia Phase 2 Clinical Trial Insights

4. Thalassemia Phase 1 Clinical Trial Insights

5. Thalassemia Preclinical Research Insights

6. Thalassemia Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/j3sw64

Copyright: 
Copyright Business Wire 2019